UC2288 NEW

Price	$41	$97	$147
Package	1mg	5mg	10mg

Min. Order:
Supply Ability:	10g
Update Time:	2024-11-19

Product Details

Product Name: UC2288	CAS No.: 1394011-91-6
Purity: 99.75%	Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

Name	UC2288
Description	UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability.
In vitro	UC2288 (0-10 μM; 24 hours) reduces p21 mRNA expression through transcriptional or post-transcriptional mechanisms, independent of p53, with no inhibition of VEGFR2 and Raf kinases, even at 10 μM[1].
In vivo	UC2288 (10 mg/kg; i.p.) attenuates MPTP-induced behavioral impairment, prevents activation of MAPK pathway in the MPTP-treated mice brain. MPTP treatment raises TNF-α, IL-6 and IL-1β levels in MPTP treated mice brain, but UC2288 signicantly decreases MPTP-induced TNF-α, IL-6 levels, but IL-1β is not decreased in brain[2].UC2888 (15 mg/kg; oral) co-treatment with imetelstat significantly suppresses tumor growth and does not effect mice weight[3].
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 48 mg/mL (99.62 mM), Sonication is recommended.
Keywords	Attenuator \| 786-O \| Inhibitor \| MDM-2/p53 \| UC 2288 \| inhibit \| ovarian \| UC2288 \| RCC \| HK2 \| p21 \| sorafenib \| UC-2288 \| p53-mutant \| cancer
Inhibitors Related	Milademetan \| Alrizomadlin \| Rotenone \| XI-006 \| RG7112 \| DPBQ \| BAY 1892005 \| Indole-3-carbinol \| Idasanutlin \| Navtemadlin \| RITA \| P53R3
Related Compound Libraries	Anti-Colorectal Cancer Compound Library \| Anti-Lung Cancer Compound Library \| Anti-Pancreatic Cancer Compound Library \| Bioactive Compound Library \| Anti-Cancer Metabolism Compound Library \| Orally Active Compound Library \| PPI Inhibitor Library \| Anti-Aging Compound Library \| Bioactive Compounds Library Max \| Transcription Factor-Targeted Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.